Incremental cost effectiveness ratio | |||||||
---|---|---|---|---|---|---|---|
Strategy | New infections | Symptom days | Neonatal infections | Cost | Cost per adult infection averted | Cost per symptom day averted | Cost per neonatal infection averted |
HSV-2 = herpes simplex virus type 2; ELISA = enzyme linked immunosorbent assay; WB = western blot. All cost effectiveness ratios rounded to the nearest $100. Cost effectiveness ratios derived from data in the table may be slightly different from those presented here, because of rounding. | |||||||
Do nothing | 170 | 5350 | 0.200 | $175 000 | – | – | – |
ELISA→WB | 132 | 4040 | 0.096 | $495 000 | $8200 | $240 | $3 075 000 |
ELISA alone | 133 | 4080 | 0.099 | $506 000 | Dominated | Dominated | Dominated |
WB | 130 | 3990 | 0.091 | $590 000 | $63 600 | $6400 | $19 080 000 |
Universal condom use | 130 | 3990 | 0.091 | $981 000 | Dominated | Dominated | Dominated |